SVP Worldwide Announces Global Launch of Three New PFAFF® Sewing Machines: creative expression™ 750, quilt expression™ 725, and expression™ 715

15.8.2025 00:33:00 CEST | Business Wire | Press Release

SVP Worldwide, the parent company of PFAFF®, SINGER®, and HUSQVARNA® VIKING® sewing brands, today announced the highly anticipated global launch of three new PFAFF sewing machines: the creative expression 750, quilt expression 725, and expression 715. These machines combine precision engineering, cutting-edge technology, and the timeless craftsmanship PFAFF is known for.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250814267636/en/

SVP Worldwide, the parent company of PFAFF (R), launches three new sewing machines: the creative expression 750, quilt expression 725 and expression 715. The machines combine precision engineering, cutting-edge technology, and the timeless craftsmanship PFAFF is known for globally.

The new models will be available for purchase beginning August 14, 2025 on PFAFF.com and at authorized PFAFF Dealer locations across the United States and Europe. Expanded global distribution in Latin America and Asia Pacific is planned throughout Q3 and Q4 of 2025.

"This launch represents an exciting new chapter for PFAFF and for passionate sewists around the world," said Rob Will, CEO of SVP Worldwide. "These three machines are designed to inspire creativity and confidence, offering the precision and innovation that our customers expect from the PFAFF brand. We can’t wait to see the extraordinary projects our ‘PFAFFies’ will bring to life with this new lineup."

The new expression series machines showcase advanced features tailored to both serious hobbyists and professional sewists. All models offer:

Built-in connectivity to the CREATIVATE™ digital platform of creative tools
Large color capacitive touch screens for an intuitive, modern sewing experience
Automatic Needle Threaders eliminate threading frustration
Exclusive PFAFF stitch techniques for distinctive embellishments

The creative expression 750 and quilt expression 725 also feature adjustable laser sewing guidance, enabling users to achieve unmatched accuracy for complex projects.

"The new PFAFF expression series brings together precision and innovation in a way that truly elevates the sewing experience," said Jason Zielke, Chief Product and Technology Officer at SVP Worldwide. "We are especially proud of the new Hoop Scanning feature on the creative expression 750, which allows a sewist to see their hooped project on the 8” color touch screen for a more accurate placement of the embroidery before stitching."

The launch of the PFAFF creative expression 750, quilt expression 725, and expression 715 reaffirms SVP Worldwide’s commitment to empowering creators worldwide with products that push the boundaries of sewing technology and innovation.

For more information or to locate a dealer, visit www.pfaff.com.

PFAFF, SINGER, VIKING, CREATIVE EXPRESSION, QUILT EXPRESSION, EXPRESSION and CREATIVATE are exclusive trademarks of Singer Sourcing Limited LLC or its Affiliates. HUSQVARNA and the “H” Crown Device are trademarks of Husqvarna AB and are used under license. © 2025 Singer Sourcing Limited LLC or its Affiliates. All rights reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250814267636/en/

Contacts

Media Inquiries:
Devon Smiddy
Sr. Director of Global Marketing, SVP Worldwide
devon.smiddy@svpworldwide.com

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press Release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press Release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 14:00:00 CEST | Press Release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press Release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom